Atlas Trials

Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency

Clinical trial NCT05345171 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05345171
Sponsor
Ultragenyx Pharmaceutical Inc
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
OTC Deficiency
Start date
2022-10-18
Primary completion
2027-09-01
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.